Extended evaluation of a phase 1/2 trial on dosing, safety, immunogenicity, and overall survival after immunizations with an advanced-generation Ad5 [E1-, E2b-]-CEA(6D) vaccine in late-stage colorectal cancer

Novel adenoviral vector induces T-cell responses despite anti-adenoviral neutralizing antibodies in colorectal cancer patients

(2013) Michael A. Morse et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

Cancer vaccines targeting carcinoembryonic antigen: state-of-the-art and future promise

(2013) Sofia R Gameiro et al.   Expert Review of Vaccines

A non-oncogenic HPV 16 E6/E7 vaccine enhances treatment of HPV expressing tumors

(2012) B G Wieking et al.   CANCER GENE THERAPY

Therapeutic Cancer Vaccines: Current Status and Moving Forward

(2012) J. Schlom   JNCI-Journal of the National Cancer Institute

Control of SIV infection and subsequent induction of pandemic H1N1 immunity in rhesus macaques using an Ad5 [E1-, E2b-] vector platform

(2012) Elizabeth S. Gabitzsch et al.   VACCINE

An Ad5[E1-, E2b-]-HER2/neu vector induces immune responses and inhibits HER2/neu expressing tumor progression in Ad5 immune mice

(2011) E S Gabitzsch et al.   CANCER GENE THERAPY

Prevention of influenza virus shedding and protection from lethal H1N1 challenge using a consensus 2009 H1N1 HA and NA adenovirus vector vaccine

(2011) Frank R. Jones et al.   VACCINE

Induction and comparison of SIV immunity in Ad5 naïve and Ad5 immune non-human primates using an Ad5 [E1-, E2b-] based vaccine

(2011) Elizabeth S. Gabitzsch et al.   VACCINE

International seroepidemiology of adenovirus serotypes 5, 26, 35, and 48 in pediatric and adult populations

(2011) Dan H. Barouch et al.   VACCINE

Anti-tumor immunotherapy despite immunity to adenovirus using a novel adenoviral vector Ad5 [E1-, E2b-]-CEA

(2010) Elizabeth S. Gabitzsch et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

Sipuleucel-T Immunotherapy for Castration-Resistant Prostate Cancer

(2010) Philip W. Kantoff et al.   NEW ENGLAND JOURNAL OF MEDICINE

Integrated data from 2 randomized, double-blind, placebo-controlled, phase 3 trials of active cellular immunotherapy with sipuleucel-T in advanced prostate cancer

(2009) Celestia S. Higano et al.   CANCER

Optimization of vaccine responses with an E1, E2b and E3-deleted Ad5 vector circumvents pre-existing anti-vector immunity

(2009) T Osada et al.   CANCER GENE THERAPY

The Prioritization of Cancer Antigens: A National Cancer Institute Pilot Project for the Acceleration of Translational Research

(2009) M. A. Cheever et al.   CLINICAL CANCER RESEARCH

Overcoming pre-existing adenovirus immunity by genetic engineering of adenovirus-based vectors

(2009) Sergey S Seregin et al.   EXPERT OPINION ON BIOLOGICAL THERAPY

Novel Adenovirus type 5 vaccine platform induces cellular immunity against HIV-1 Gag, Pol, Nef despite the presence of Ad5 immunity

(2009) Elizabeth S. Gabitzsch et al.   VACCINE

New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)

(2008) E.A. Eisenhauer et al.   EUROPEAN JOURNAL OF CANCER

A preliminary and comparative evaluation of a novel Ad5 [E1-, E2b-] recombinant-based vaccine used to induce cell mediated immune responses

(2008) Elizabeth S. Gabitzsch et al.   IMMUNOLOGY LETTERS

K-rasMutations and Benefit from Cetuximab in Advanced Colorectal Cancer

(2008) Christos S. Karapetis et al.   NEW ENGLAND JOURNAL OF MEDICINE